<p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, offering durable responses and prolonged survival. However, these therapies also present unique challenges, particularly with the onset of immune-related adverse events (irAEs), which can manifest during treatment either acutely and/or become chronic or emerge long after treatment cessation. Delayed, chronic, and re-emergent irAEs often require tailored survivorship care, including coordination across multiple…
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Journal for ImmunoTherapy of Cancer | | Flores, T. F., Tonorezos, E. S., Bhatia, S., Brahmer, J. R., Cappelli, L. C., Cooper, M., Davies, M., Guild, S., Gunturu, K., Haanen, J. B. A. G., Johnson, D. B., Lacouture, M. E., Leidner, R., Mitchell, S., Moledina, D. G., Moslehi, J., Naidoo, J., Obeid, M., Postow, M., Puzanov, I., Reid, M. E., Santomasso, B. D., Schadendorf, D., Silk, A. W., Sullivan, R. J., Walunas, T., Wang, Y., Ascierto, P. A., Ernstoff, M. S.
Topics: blood-cancer, immunotherapy, prevention
Read the full article at Journal for ImmunoTherapy of Cancer